Accessibility settings

This paper is in the following e-collection/theme issue:

Infoveillance and Social Listening (321) Bots and AI Approaches to Detect and Counter Misinformation (23) Health and Risk Communication (86) Misinformation and Disinformation Outbreaks and Information Prevalence Studies (103) Infoveillance, Infodemiology, Digital Disease Surveillance, Infodemic Management (1156) Pharmacovigilance (181) Medicine 2.0: Social Media, Open, Participatory, Collaborative Medicine (1960)

Published on in Vol 5 (2025)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/73619, first published .
Harnessing Facebook to Investigate Real-World Mentions of Adverse Events of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications: Observational Study of Facebook Posts From 2022 to 2024

Harnessing Facebook to Investigate Real-World Mentions of Adverse Events of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications: Observational Study of Facebook Posts From 2022 to 2024

Harnessing Facebook to Investigate Real-World Mentions of Adverse Events of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications: Observational Study of Facebook Posts From 2022 to 2024

Authors of this article:

Amrutha S Alibilli1 Author Orcid Image ;   Vidur Jain1 Author Orcid Image ;   Heran Mane1 Author Orcid Image ;   Xiaohe Yue1 Author Orcid Image ;   Alexandria Ratzki-Leewing2, 3 Author Orcid Image ;   Junaid S Merchant1 Author Orcid Image ;   Shaniece Criss4 Author Orcid Image ;   Quynh C Nguyen5 Author Orcid Image ;   Rozalina G McCoy2, 3, 6 Author Orcid Image ;   Thu T Nguyen1, 3 Author Orcid Image
Article Authors Cited by (3) Tweetations Metrics

Journals

  1. Sun Y, Veccia D, Liu B, Tse W, Fass R, Song G. Diagnostic Evaluation of an Increased Risk of Developing Small Intestinal Bacterial Overgrowth Associated with Glucagon-like Peptide-1 (GLP-1) Receptor Agonists and Dual GLP-1/GIP Receptor Agonists: A Global Retrospective Multicenter Cohort Analysis. Diagnostics 2025;15(17):2264 View
  2. Hindi A, Mekkawy M, Shokr H. Psychiatric Adverse Events and Administration Challenges Associated with GLP-1 Receptor Agonists for Weight Loss: A Real-World Analysis. Pharmaceuticals 2026;19(3):365 View
  3. Tejera-Pérez C. Viral medicine: social media and new expectations of obesity treatment. The Lancet Diabetes & Endocrinology 2026 View